Discovery of geranylgeranyltransferase-I inhibitors with novel scaffolds by the means of quantitative structure-activity relationship modeling, virtual screening, and experimental validation

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4210-4220

  Peterson, Yuri K ^a,b   Wang, Xiang S ^b   Casey, Patrick J ^a,c   Tropsha, Alexander ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NONE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; GERANYLGERANYLTRANSFERASE I; GERANYLGERANYLTRANSFERASE I INHIBITOR; GERANYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; PROTEIN CDC42; RAC PROTEIN; RAP1 PROTEIN; RHO FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; DRUG SCREENING; DRUG SELECTIVITY; ENZYME INHIBITION; GERANYLGERANYLATION; IN VITRO STUDY; MOLECULAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RELIABILITY; VALIDATION PROCESS;

ALGORITHMS; ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL LINE; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS;

EID: 67650717853     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8013772     Document Type: Article

References (60)

1. Zhang, F. L.; Casey, P. J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 1996, 65, 241-269.
2. Cox, A. D.; Der, C. J. Farnesyltransferase inhibitors: promises and realities. Curr. Opin. Pharmacol. 2002, 2, 388-393.
3. Winter-Vann, A. M.; Casey, P. J. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat. Rev. Cancer 2005, 5, 405-412.
4. Casey, P. J.; Seabra, M. C. Protein prenyltransferases. J. Biol. Chem. 1996, 271, 5289-5292.
5. Sebti, S. M.; Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert. Opin. Invest. Drugs 2000, 9, 2767-2782.
6. Reid, T. S.; Terry, K. L.; Casey, P. J.; Beese, L. S. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J. Mol. Biol. 2004, 343, 417-433.
7. Kohl, N. E.; Conner, M. W.; Gibbs, J. B.; Graham, S. L.; Hartman, G. D.; Oliff, A. Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J. Cell Biochem., Suppl. 1995, 22, 145-150.
8. Karp, J. E.; Lancet, J. E. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies. Ann. Hematol. 2004, 83 (Suppl. 1), S87-S88.
9. Karp, J. E.; Lancet, J. E. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Cancer Invest. 2007, 25, 484-494.
10. Gu, W. Z.; Joseph, I.; Wang, Y. C.; Frost, D.; Sullivan, G. M.; Wang, L.; Lin, N. H.; Cohen, J.; Stoll, V. S.; Jakob, C. G.; Muchmore, S. W.; Harlan, J. E.; Holzman, T.; Walten, K. A.; Ladror, U. S.; Anderson, M. G.; Kroeger, P.; Rodriguez, L. E.; Jarvis, K. P.; Ferguson, D.; Marsh, K.; Ng, S.; Rosenberg, S. H.; Sham, H. L.; Zhang, H. A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies. Anti-Cancer Drugs 2005, 16, 1059-1069.
11. Lerner, E. C.; Zhang, T. T.; Knowles, D. B.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 1997, 15, 1283-1288.
12. El Oualid, F.; Cohen, L. H.; van der Marel, G. A.; Overhand, M. Inhibitors of protein: geranylgeranyl transferases. Curr. Med. Chem. 2006, 13, 2385-2427.
13. Chakrabarti, D.; Da Silva, T.; Barger, J.; Paquette, S.; Patel, H.; Patterson, S.; Allen, C. M. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. J. Biol. Chem. 2002, 277, 42066-42073.
14. Sagan, S. M.; Rouleau, Y.; Leggiadro, C.; Supekova, L.; Schultz, P. G.; Su, A. I.; Pezacki, J. P. The influence of cholesterol and lipid metabolism on host cell structure and hepatitis C virus replication. Biochem. Cell Biol. 2006, 84, 67-79.
15. Vasudevan, A.; Qian, Y.; Vogt, A.; Blaskovich, M. A.; Ohkanda, J.; Sebti, S. M.; Hamilton, A. D. Potent, highly selective, and nonthiol inhibitors of protein geranylgeranyltransferase-I. J. Med. Chem. 1999, 42, 1333-1340.
16. Carrico, D.; Blaskovich, M. A.; Bucher, C. J.; Sebti, S. M.; Hamilton, A. D. Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I. Bioorg. Med. Chem. 2005, 13, 677-688.
17. Vogt, A.; Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J. Biol. Chem. 1997, 272, 27224-27229.
18. Peng, H.; Carrico, D.; Thai, V.; Blaskovich, M.; Bucher, C.; Pusateri, E. E.; Sebti, S. M.; Hamilton, A. D. Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I. Org. Biomol. Chem. 2006, 4, 1768-1784.
19. Castellano, S.; Fiji, H. D.; Kinderman, S. S.; Watanabe, M.; Leon, P.; Tamanoi, F.; Kwon, O. Small-molecule inhibitors of protein geranylgeranyltransferase type I. J. Am. Chem. Soc. 2007, 129, 5843-5845.
20. Watanabe, M.; Fiji, H. D.; Guo, L.; Chan, L.; Kinderman, S. S.; Slamon, D. J.; Kwon, O.; Tamanoi, F. Inhibitors of protein geranylgeranyltransferase-I and rab geranylgeranyltransferase identified from a library of allenoate derived compounds. J. Biol. Chem. 2008, 283, 9571-9579.
21. Bergo, M. O.; Gavino, B. J.; Hong, C.; Beigneux, A. P.; McMahon, M.; Casey, P. J.; Young, S. G. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J. Clin. Invest. 2004, 113, 539-550.
22. Peterson, Y. K.; Kelly, P.; Weinbaum, C. A.; Casey, P. J. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J. Biol. Chem. 2006, 281, 12445-12450.
23. Sun, J.; Qian, Y.; Chen, Z.; Marfurt, J.; Hamilton, A. D.; Sebti, S. M. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. J. Biol. Chem. 1999, 274, 6930-6934.
24. Stark, W. W.; Blaskovich, M. A.; Johnson, B. A.; Qian, Y.; Vasudevan, A.; Pitt, B.; Hamilton, A. D.; Sebti, S. M.; Davies, P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am. J. Physiol. 1998, 275, L55-L63.
25. Li, X.; Liu, L.; Tupper, J. C.; Bannerman, D. D.; Winn, R. K.; Sebti, S. M.; Hamilton, A. D.; Harlan, J. M. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J. Biol. Chem. 2002, 277, 15309-15316.
26. Morgan, M. A.; Wegner, J.; Aydilek, E.; Ganser, A.; Reuter, C. W. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Leukemia 2003, 17, 1508-1520.
27. Dan, H. C.; Jiang, K.; Coppola, D.; Hamilton, A.; Nicosia, S. V.; Sebti, S. M.; Cheng, J. Q. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 2004, 23, 706-715.
28. Sybyl Users Manuel; Tripos, Inc.: St. Louis, MO, 2002.
29. Tropsha,A. Recent Trends in Quantitative Structure-Activity Relationships. In Burger's Medicinal Chemistry and Drug Discovery; Abraham, D., Ed.; John Wiley & Sons, Inc.: New York, 2003; pp 49-77.
30. Tropsha, A.; Cho, S. J.; Zheng, W. "New Tricks For an Old Dog": Developement and Application of Novel QSAR Methods for Rational Design of Combinatorial Chemical Libraries and Database Mining. In ACS Symposium Series; Parrill, A. L., Reddy,M. R., Eds.; American Chemical Society: Washington, DC, 2001; Vol. 719.
31. Tang, H.; Wang, X. S.; Huang, X. P.; Roth, B. L.; Butler, K. V.; Kozikowski, A. P.; Jung, M.; Tropsha, A. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation. J. Chem. Inf. Model. 2009, 49, 461-476.
32. Hsieh, J. H.; Wang, X. S.; Teotico, D.; Golbraikh, A.; Tropsha, A. Differentiation of AmpC beta-lactamase binders vs. decoys using classification kNN QSAR modeling and application of the QSAR classifier to virtual screening. J. Comput.-Aided Mol. Des. 2008, 22, 593-609.
33. Shen, M.; LeTiran, A.; Xiao, Y.; Golbraikh, A.; Kohn, H.; Tropsha, A. Quantitative structure-activity relationship analysis of functionalized amino acid anticonvulsant agents using k nearest neighbor and simulated annealing PLS methods. J. Med. Chem. 2002, 45, 2811-2823.
34. Shen, M.; Beguin, C.; Golbraikh, A.; Stables, J. P.; Kohn, H.; Tropsha, A. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds. J. Med. Chem. 2004, 47, 2356-2364.
35. Tropsha, A.; Golbraikh, A. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr. Pharm. Des. 2007, 13, 3494-3504.
36. Tropsha, A; Gramatica, P.; Gombar, V. K. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb. Sci. 2003, 22, 69-77.
37. Hoffman, B. T.; Kopajtic, T.; Katz, J. L.; Newman, A. H. 2D QSARmodeling and preliminary database searching for dopamine transporter inhibitors using genetic algorithm variable selection of Molconn Z descriptors. J. Med. Chem. 2000, 43, 4151-4159.
38. Kovatcheva, A.; Golbraikh, A.; Oloff, S.; Xiao, Y. D.; Zheng, W.; Wolschann, P.; Buchbauer, G.; Tropsha, A. Combinatorial QSAR of ambergris fragrance compounds. J. Chem. Inf. Comput. Sci. 2004, 44, 582-595.
39. Wang, X. S.; Tang, H.; Golbraikh, A.; Tropsha, A. Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F. J. Chem. Inf. Model. 2008, 48, 997-1013.
40. Polley, M. J.; Winkler, D. A.; Burden, F. R. Broad-based quantitative structure-activity relationship modeling of potency and selectivity of farnesyltransferase inhibitors using a Bayesian regularized neural network. J. Med. Chem. 2004, 47, 6230-6238.
41. Lerner, E. C.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J. Biol. Chem. 1995, 270, 26770-26773.
42. Peterson, Y.; Wang, S. X.; Casey, P.; Tropsha, A. Novel Chemical Scaffolds for Protein Geranylgeranyltransferase Type I Inhibitors. U.S. Patent and Trademark Office, 2007.
43. Qian, Y.; Vogt, A.; Vasudevan, A.; Sebti, S. M.; Hamilton, A. D. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics. Bioorg. Med. Chem. 1998, 6, 293-299.
44. Sun, J.; Blaskovich, M. A.; Knowles, D.; Qian, Y.; Ohkanda, J.; Bailey, R. D.; Hamilton, A. D.; Sebti, S. M. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 1999, 59, 4919-4926.
45. MolconnZ, version 4.05; Edusoft, LLC.: San Francisco, CA, 2003.
46. Kier, L. B.; Hall, L. H. Molecular Connectivity in Chemistry and Drug Research; Acedemic Press: New York, 1976.
47. Zheng, W.; Tropsha, A. Novel variable selection quantitative structure-property relationship approach based on the k-nearest-neighbor principle. J. Chem. Inf. Comput. Sci. 2000, 40, 185-194.
48. Golbraikh, A.; Shen, M.; Xiao, Z. Y.; Xiao, Y. D.; Lee, K. H.; Tropsha, A. Rational selection of training and test sets for the development of validated QSAR models. J. Comput.-Aided Mol. Des. 2003, 17, 241-253.
49. Sharaf, M.; Illman, D.; Kowalski, B. Chemometrics; John Wiley & Sons: New York, 1986.
50. Tropsha, A.; Zhang, W. F. Identification of the descriptor pharmacophores using variable selection QSAR: Aapplications to database mining. Curr. Pharm. Des. 2001, 7, 599-612.
51. Golbraikh, A.; Tropsha, A. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J. Comput.-Aided Mol. Des. 2002, 16, 357-369.
52. Zhang, S.; Golbraikh, A.; Oloff, S.; Kohn, H.; Tropsha, A. A novel automated lazy learning QSAR (ALL-QSAR) approach: method development, applications, and virtual screening of chemical databases using validated ALL-QSAR models. J. Chem. Inf. Model. 2006, 46, 1984-1995.
53. Wold, S. a. E. L. Statistical Validation of QSAR Results. In Chemometrics Methods in Molecular Design; Van De Waterbeemd, H., Ed.; VCH: Weinheim, Germany, 1995; pp 309-318.
54. Irwin, J. J.; Shoichet, B. K. ZINC, a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 45, 177-182.
55. Maybridge Chemical Company, Maybridge, U.K., 2004.
56. Thomson Scientific. World Drug Index Database. 2007.
57. Progenitor Databases. http://www.chemizon.com (accessed 2006).
58. Xue, L.; Stahura, F. L.; Godden, J. W.; Bajorath, J. Mini-fingerprints detect similar activity of receptor ligands previously recognized only by three-dimensional pharmacophore-based methods. J. Chem. Inf. Comput. Sci. 2001, 41, 394-401.
59. Zhang, F. L.; Diehl, R. E.; Kohl, N. E.; Gibbs, J. B.; Giros, B.; Casey, P. J.; Omer, C. A. cDNA cloning and expression of rat and human protein geranylgeranyltransferase type-I. J. Biol. Chem. 1994, 269, 3175-3180.
60. Zhang, F. L.; Moomaw, J. F.; Casey, P. J. Properties and kinetic mechanism of recombinant mammalian protein geranylgeranyltransferase type I. J. Biol. Chem. 1994, 269, 23465-23470.